請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29705
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 顧記華(Jih-Hwa Guh) | |
dc.contributor.author | Jui-Ling Hsu | en |
dc.contributor.author | 徐瑞苓 | zh_TW |
dc.date.accessioned | 2021-06-13T01:15:34Z | - |
dc.date.available | 2009-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-20 | |
dc.identifier.citation | 1. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11, 97-107 (2004).
2. Bressac, B., Galvin, K.M., Liang, T.J., Isselbacher, K.J., Wands, J.R. & Ozturk, M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 87, 1973-1977 (1990). 3. Chen, H.L., Chiu, T.S., Chen, P.J. & Chen, D.S. Cytogenetic studies on human liver cancer cell lines. Cancer Genet Cytogenet 65, 161-166 (1993). 4. Kerr, J.F., Wyllie, A.H. & Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26, 239-257 (1972). 5. Kroemer, G., El-Deiry, W.S., Golstein, P., Peter, M.E., Vaux, D., Vandenabeele, P., Zhivotovsky, B., Blagosklonny, M.V., Malorni, W., Knight, R.A., Piacentini, M., Nagata, S. & Melino, G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 12 Suppl 2, 1463-1467 (2005). 6. Savill, J.S., Wyllie, A.H., Henson, J.E., Walport, M.J., Henson, P.M. & Haslett, C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 83, 865-875 (1989). 7. Bremer, E., van Dam, G., Kroesen, B.J., de Leij, L. & Helfrich, W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 12, 382-393 (2006). 8. Green, D.R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science 305, 626-629 (2004). 9. Breckenridge, D.G. & Xue, D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr Opin Cell Biol 16, 647-652 (2004). 10. Saelens, X., Festjens, N., Vande Walle, L., van Gurp, M., van Loo, G. & Vandenabeele, P. Toxic proteins released from mitochondria in cell death. Oncogene 23, 2861-2874 (2004). 11. Fulda, S. & Debatin, K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811 (2006). 12. Shi, Y. Apoptosome: the cellular engine for the activation of caspase-9. Structure 10, 285-288 (2002). 13. Li, L.Y., Luo, X. & Wang, X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412, 95-99 (2001). 14. Cheng, E.H., Sheiko, T.V., Fisher, J.K., Craigen, W.J. & Korsmeyer, S.J. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 301, 513-517 (2003). 15. Ruffolo, S.C. & Shore, G.C. BCL-2 selectively interacts with the BID-induced open conformer of BAK, inhibiting BAK auto-oligomerization. J Biol Chem 278, 25039-25045 (2003). 16. Letai, A., Bassik, M.C., Walensky, L.D., Sorcinelli, M.D., Weiler, S. & Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192 (2002). 17. Lamkanfi, M., Festjens, N., Declercq, W., Vanden Berghe, T. & Vandenabeele, P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 14, 44-55 (2007). 18. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9, 459-470 (2002). 19. Schwartz, G.K. & Shah, M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23, 9408-9421 (2005). 20. MacLachlan, T.K., Sang, N. & Giordano, A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5, 127-156 (1995). 21. Kaldis, P., Russo, A.A., Chou, H.S., Pavletich, N.P. & Solomon, M.J. Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 9, 2545-2560 (1998). 22. Rutkowski, D.T. & Kaufman, R.J. A trip to the ER: coping with stress. Trends Cell Biol 14, 20-28 (2004). 23. Szegezdi, E., Logue, S.E., Gorman, A.M. & Samali, A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7, 880-885 (2006). 24. Boyce, M. & Yuan, J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 13, 363-373 (2006). 25. Ma, Y. & Hendershot, L.M. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4, 966-977 (2004). 26. Yan, W., Frank, C.L., Korth, M.J., Sopher, B.L., Novoa, I., Ron, D. & Katze, M.G. Control of PERK eIF2alpha kinase activity by the endoplasmic reticulum stress-induced molecular chaperone P58IPK. Proc Natl Acad Sci U S A 99, 15920-15925 (2002). 27. van Huizen, R., Martindale, J.L., Gorospe, M. & Holbrook, N.J. P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2alpha signaling. J Biol Chem 278, 15558-15564 (2003). 28. Oakes, S.A., Lin, S.S. & Bassik, M.C. The control of endoplasmic reticulum-initiated apoptosis by the BCL-2 family of proteins. Curr Mol Med 6, 99-109 (2006). 29. Qu, L., Huang, S., Baltzis, D., Rivas-Estilla, A.M., Pluquet, O., Hatzoglou, M., Koumenis, C., Taya, Y., Yoshimura, A. & Koromilas, A.E. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev 18, 261-277 (2004). 30. Jiang, H.Y., Wek, S.A., McGrath, B.C., Scheuner, D., Kaufman, R.J., Cavener, D.R. & Wek, R.C. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 23, 5651-5663 (2003). 31. Luethy, J.D. & Holbrook, N.J. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. Cancer Res 52, 5-10 (1992). 32. de Boer, L., Gray, P.P. & Sunstrom, N.A. Enhanced productivity of G1 phase Chinese hamster ovary cells using the GADD153 promoter. Biotechnol Lett 26, 61-65 (2004). 33. Barone, M.V., Crozat, A., Tabaee, A., Philipson, L. & Ron, D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev 8, 453-464 (1994). 34. Gotoh, T., Terada, K., Oyadomari, S. & Mori, M. hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death Differ 11, 390-402 (2004). 35. McCullough, K.D., Martindale, J.L., Klotz, L.O., Aw, T.Y. & Holbrook, N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 21, 1249-1259 (2001). 36. Marciniak, S.J., Yun, C.Y., Oyadomari, S., Novoa, I., Zhang, Y., Jungreis, R., Nagata, K., Harding, H.P. & Ron, D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 18, 3066-3077 (2004). 37. Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H.P. & Ron, D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664-666 (2000). 38. Yoneda, T., Imaizumi, K., Oono, K., Yui, D., Gomi, F., Katayama, T. & Tohyama, M. Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J Biol Chem 276, 13935-13940 (2001). 39. Zong, W.X., Li, C., Hatzivassiliou, G., Lindsten, T., Yu, Q.C., Yuan, J. & Thompson, C.B. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol 162, 59-69 (2003). 40. Scorrano, L., Oakes, S.A., Opferman, J.T., Cheng, E.H., Sorcinelli, M.D., Pozzan, T. & Korsmeyer, S.J. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 300, 135-139 (2003). 41. Nakagawa, T. & Yuan, J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 150, 887-894 (2000). 42. Brown, J.M. & Giaccia, A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416 (1998). 43. Lee, A.S. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26, 504-510 (2001). 44. Patierno, S.R., Tuscano, J.M., Kim, K.S., Landolph, J.R. & Lee, A.S. Increased expression of the glucose-regulated gene encoding the Mr 78,000 glucose-regulated protein in chemically and radiation-transformed C3H 10T1/2 mouse embryo cells. Cancer Res 47, 6220-6224 (1987). 45. Bini, L., Magi, B., Marzocchi, B., Arcuri, F., Tripodi, S., Cintorino, M., Sanchez, J.C., Frutiger, S., Hughes, G., Pallini, V., Hochstrasser, D.F. & Tosi, P. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18, 2832-2841 (1997). 46. Fernandez, P.M., Tabbara, S.O., Jacobs, L.K., Manning, F.C., Tsangaris, T.N., Schwartz, A.M., Kennedy, K.A. & Patierno, S.R. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59, 15-26 (2000). 47. Shen, J., Hughes, C., Chao, C., Cai, J., Bartels, C., Gessner, T. & Subjeck, J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci U S A 84, 3278-3282 (1987). 48. Chatterjee, S., Cheng, M.F., Berger, R.B., Berger, S.J. & Berger, N.A. Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide. Cancer Res 55, 868-873 (1995). 49. Sacchi, C.M. & Schiaffonati, L. The effect of etoposide (VP-16) on mouse L fibroblasts: modulation of stress response, growth and apoptosis genes. Anticancer Res 16, 3659-3664 (1996). 50. Koomagi, R., Mattern, J. & Volm, M. Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res 19, 4333-4336 (1999). 51. Tomida, A. & Tsuruo, T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 14, 169-177 (1999). 52. Brewer, J.W., Hendershot, L.M., Sherr, C.J. & Diehl, J.A. Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc Natl Acad Sci U S A 96, 8505-8510 (1999). 53. Martinez, J.A., Torres-Negron, I., Amigo, L.A., Roldan, R.A., Mendez, A. & Banerjee, D.K. Tunicamycin inhibits capillary endothelial cell proliferation by inducing apoptosis. Targeting dolichol-pathway for generation of new anti-angiogenic therapeutics. Adv Exp Med Biol 476, 197-208 (2000). 54. Savage, K.E. & Baur, P.S. Effect of tunicamycin, an inhibitor of protein glycosylation, on division of tumour cells in vitro. J Cell Sci 64, 295-306 (1983). 55. Engstrom, W. & Larsson, O. The effects of glycosylation inhibitors on the proliferation of a spontaneously transformed cell line (3T6) in vitro. J Cell Sci 90 ( Pt 3), 447-455 (1988). 56. Carlberg, M. & Larsson, O. Role of N-linked glycosylation in cell-cycle progression and initiation of DNA synthesis in tumor-transformed human fibroblasts. Anticancer Res 13, 167-171 (1993). 57. Inesi, G., Hua, S., Xu, C., Ma, H., Seth, M., Prasad, A.M. & Sumbilla, C. Studies of Ca2+ ATPase (SERCA) inhibition. J Bioenerg Biomembr 37, 365-368 (2005). 58. Shinohara, T., Ikesugi, K. & Mulhern, M.L. Cataracts: role of the unfolded protein response. Med Hypotheses 66, 365-370 (2006). 59. Nebenfuhr, A., Ritzenthaler, C. & Robinson, D.G. Brefeldin A: deciphering an enigmatic inhibitor of secretion. Plant Physiol 130, 1102-1108 (2002). 60. Wang, J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3, 430-440 (2002). 61. Cortes, F., Pastor, N., Mateos, S. & Dominguez, I. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 543, 59-66 (2003). 62. Sakaguchi, A. & Kikuchi, A. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J Cell Sci 117, 1047-1054 (2004). 63. Champoux, J.J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70, 369-413 (2001). 64. Leppard, J.B. & Champoux, J.J. Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma 114, 75-85 (2005). 65. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6, 789-802 (2006). 66. Larsen, A.K., Escargueil, A.E. & Skladanowski, A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99, 167-181 (2003). 67. Roos, W.P. & Kaina, B. DNA damage-induced cell death by apoptosis. Trends Mol Med 12, 440-450 (2006). 68. Pizzolato, J.F. & Saltz, L.B. The camptothecins. Lancet 361, 2235-2242 (2003). 69. Sriram, D., Yogeeswari, P., Thirumurugan, R. & Bal, T.R. Camptothecin and its analogues: a review on their chemotherapeutic potential. Nat Prod Res 19, 393-412 (2005). 70. Liu, L.F. & D'Arpa, P. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Important Adv Oncol, 79-89 (1992). 71. Desai, S.D., Li, T.K., Rodriguez-Bauman, A., Rubin, E.H. & Liu, L.F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61, 5926-5932 (2001). 72. Takano, H., Kohno, K., Matsuo, K., Matsuda, T. & Kuwano, M. DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 3, 323-330 (1992). 73. Kawanami, K., Nakamura, T., Ono, M., Kusano, T., Okada, K., Kikuchi, A., Adachi, N., Kohno, K., Higashi, K. & Kuwano, M. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Oncol Res 8, 197-206 (1996). 74. Asano, T., An, T., Zwelling, L.A., Takano, H., Fojo, A.T. & Kleinerman, E.S. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncol Res 8, 101-110 (1996). 75. Perego, P., Capranico, G., Supino, R. & Zunino, F. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 5, 645-649 (1994). 76. Ohashi, N., Fujiwara, Y., Yamaoka, N., Katoh, O., Satow, Y. & Yamakido, M. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn J Cancer Res 87, 1280-1287 (1996). 77. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L.F. & Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50, 7962-7965 (1990). 78. Chen, S., Gomez, S.P., McCarley, D. & Mainwaring, M.G. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother Pharmacol 49, 347-355 (2002). 79. Jezek, P. & Hlavata, L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol 37, 2478-2503 (2005). 80. Fruehauf, J.P. & Meyskens, F.L., Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 13, 789-794 (2007). 81. Gottesman, M.M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62, 385-427 (1993). 82. Loo, T.W. & Clarke, D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206, 173-185 (2005). 83. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P. & et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994). 84. Borgne, A., Versteege, I., Mahe, M., Studeny, A., Leonce, S., Naime, I., Rodriguez, M., Hickman, J.A., Meijer, L. & Golsteyn, R.M. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene 25, 7361-7372 (2006). 85. Hughes, C.S., Shen, J.W. & Subjeck, J.R. Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res 49, 4452-4454 (1989). 86. Vichi, P.J. & Tritton, T.R. Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A. Cancer Res 53, 5237-5243 (1993). 87. Thakkar, N.S. & Potten, C.S. Inhibition of doxorubicin-induced apoptosis in vivo by 2-deoxy-D-glucose. Cancer Res 53, 2057-2060 (1993). 88. Tomida, A., Yun, J. & Tsuruo, T. Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. Int J Cancer 68, 391-396 (1996). 89. Kellogg, G.E., Scarsdale, J.N. & Fornari, F.A., Jr. Identification and hydropathic characterization of structural features affecting sequence specificity for doxorubicin intercalation into DNA double-stranded polynucleotides. Nucleic Acids Res 26, 4721-4732 (1998). 90. Navarro, R., Busnadiego, I., Ruiz-Larrea, M.B. & Ruiz-Sanz, J.I. Superoxide anions are involved in doxorubicin-induced ERK activation in hepatocyte cultures. Ann N Y Acad Sci 1090, 419-428 (2006). 91. Wang, L.G., Liu, X.M., Kreis, W. & Budman, D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44, 355-361 (1999). 92. Seyb, K.I., Ansar, S., Bean, J. & Michaelis, M.L. beta-Amyloid and endoplasmic reticulum stress responses in primary neurons: effects of drugs that interact with the cytoskeleton. J Mol Neurosci 28, 111-123 (2006). 93. Salti, G.I., Grewal, S., Mehta, R.R., Das Gupta, T.K., Boddie, A.W., Jr. & Constantinou, A.I. Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells. Eur J Cancer 36, 796-802 (2000). 94. Gong, L., Li, Y., Nedeljkovic-Kurepa, A. & Sarkar, F.H. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22, 4702-4709 (2003). 95. Yeh, T.C., Chiang, P.C., Li, T.K., Hsu, J.L., Lin, C.J., Wang, S.W., Peng, C.Y. & Guh, J.H. Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult. Biochem Pharmacol 73, 782-792 (2007). 96. Samejima, K., Svingen, P.A., Basi, G.S., Kottke, T., Mesner, P.W., Jr., Stewart, L., Durrieu, F., Poirier, G.G., Alnemri, E.S., Champoux, J.J., Kaufmann, S.H. & Earnshaw, W.C. Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. J Biol Chem 274, 4335-4340 (1999). 97. Shen, J.W., Subjeck, J.R., Lock, R.B. & Ross, W.E. Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response. Mol Cell Biol 9, 3284-3291 (1989). 98. Yun, J., Tomida, A., Nagata, K. & Tsuruo, T. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 7, 583-590 (1995). 99. Gosky, D. & Chatterjee, S. Down-regulation of topoisomerase II alpha is caused by up-regulation of GRP78. Biochem Biophys Res Commun 300, 327-332 (2003). 100. Gray, M.D., Mann, M., Nitiss, J.L. & Hendershot, L.M. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Mol Pharmacol 68, 1699-1707 (2005). 101. Sorensen, M., Sehested, M., Christensen, I.J., Larsen, J.K. & Jensen, P.B. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation. Br J Cancer 77, 2152-2161 (1998). 102. Feng, L.F., Zhong, M., Lei, X.Y., Zhu, B.Y., Tang, S.S. & Liao, D.F. Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. J Drug Target 14, 21-26 (2006). 103. Kim, B.C., Mamura, M., Choi, K.S., Calabretta, B. & Kim, S.J. Transforming growth factor beta 1 induces apoptosis through cleavage of BAD in a Smad3-dependent mechanism in FaO hepatoma cells. Mol Cell Biol 22, 1369-1378 (2002). 104. Reddy, R.K., Mao, C., Baumeister, P., Austin, R.C., Kaufman, R.J. & Lee, A.S. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278, 20915-20924 (2003). 105. Kaina, B. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol 66, 1547-1554 (2003). 106. Vousden, K.H. & Lu, X. Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604 (2002). 107. Zhang, X.W. & Xu, B. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs 11, 747-756 (2000). 108. Li, J., Lee, B. & Lee, A.S. Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 281, 7260-7270 (2006). 109. Shibue, T., Suzuki, S., Okamoto, H., Yoshida, H., Ohba, Y., Takaoka, A. & Taniguchi, T. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. Embo J 25, 4952-4962 (2006). 110. Lee, A.S. The accumulation of three specific proteins related to glucose-regulated proteins in a temperature-sensitive hamster mutant cell line K12. J Cell Physiol 106, 119-125 (1981). 111. Clifford, B., Beljin, M., Stark, G.R. & Taylor, W.R. G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 63, 4074-4081 (2003). 112. Rao, R.V., Peel, A., Logvinova, A., del Rio, G., Hermel, E., Yokota, T., Goldsmith, P.C., Ellerby, L.M., Ellerby, H.M. & Bredesen, D.E. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett 514, 122-128 (2002). 113. Chatterjee, S., Cheng, M.F., Berger, S.J. & Berger, N.A. Induction of M(r) 78,000 glucose-regulated stress protein in poly(adenosine diphosphate-ribose) polymerase- and nicotinamide adenine dinucleotide-deficient V79 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide. Cancer Res 54, 4405-4411 (1994). 114. Zu, K., Bihani, T., Lin, A., Park, Y.M., Mori, K. & Ip, C. Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 25, 546-554 (2006). 115. Cai, B., Tomida, A., Mikami, K., Nagata, K. & Tsuruo, T. Down-regulation of epidermal growth factor receptor-signaling pathway by binding of GRP78/BiP to the receptor under glucose-starved stress conditions. J Cell Physiol 177, 282-288 (1998). 116. Liu, G., Shang, Y. & Yu, Y. Induced endoplasmic reticulum (ER) stress and binding of over-expressed ER specific chaperone GRP78/BiP with dimerized epidermal growth factor receptor in mammalian cells exposed to low concentration of N-methyl-N'-nitro-N-nitrosoguanidine. Mutat Res 596, 12-21 (2006). 117. Busse, D., Doughty, R.S., Ramsey, T.T., Russell, W.E., Price, J.O., Flanagan, W.M., Shawver, L.K. & Arteaga, C.L. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275, 6987-6995 (2000). 118. Wang, H.C., Huang, W., Lai, M.D. & Su, I.J. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 97, 683-688 (2006). 119. Chua, P.K., Wang, R.Y., Lin, M.H., Masuda, T., Suk, F.M. & Shih, C. Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus. J Virol 79, 13483-13496 (2005). 120. Li, B., Gao, B., Ye, L., Han, X., Wang, W., Kong, L., Fang, X., Zeng, Y., Zheng, H., Li, S., Wu, Z. & Ye, L. Hepatitis B virus X protein (HBx) activates ATF6 and IRE1-XBP1 pathways of unfolded protein response. Virus Res 124, 44-49 (2007). 121. Timur, M., Akbas, S.H. & Ozben, T. The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line. Acta Biochim Pol 52, 897-902 (2005). 122. Choi, C.H., Kim, H.S., Kweon, O.S., Lee, T.B., You, H.J., Rha, H.S., Jeong, J.H., Lim, D.Y., Min, Y.D., Kim, M.S. & Chung, M.H. Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. Mol Cells 10, 38-46 (2000). 123. Harding, H.P., Zhang, Y., Zeng, H., Novoa, I., Lu, P.D., Calfon, M., Sadri, N., Yun, C., Popko, B., Paules, R., Stojdl, D.F., Bell, J.C., Hettmann, T., Leiden, J.M. & Ron, D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11, 619-633 (2003). 124. Lai, M.T., Huang, K.L., Chang, W.M. & Lai, Y.K. Geldanamycin induction of grp78 requires activation of reactive oxygen species via ER stress responsive elements in 9L rat brain tumour cells. Cell Signal 15, 585-595 (2003). 125. Lai, W.L. & Wong, N.S. ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene. Free Radic Biol Med 38, 1585-1593 (2005). 126. van der Kolk, D.M., de Vries, E.G., van Putten, W.J., Verdonck, L.F., Ossenkoppele, G.J., Verhoef, G.E. & Vellenga, E. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6, 3205-3214 (2000). 127. Ledoux, S., Yang, R., Friedlander, G. & Laouari, D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 63, 7284-7290 (2003). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29705 | - |
dc.description.abstract | 肝癌是常見的惡性腫瘤且常對於臨床化學治療的藥物產生抗藥性。Camptothecin與etoposide為臨床上已廣泛使用的藥物,其作用機轉分別為抑制拓樸異構酵素I和II。Tunicamycin能經由抑制蛋白質N端的醣化作用來引起大量未折疊蛋白的產生,因此可作為內質網壓力的誘導劑。實驗數據顯示合併使用tunicamycin時,可減少在肝癌細胞Hep3B中camptothecin/etoposide引起的細胞凋亡現象,而另一株肝癌細胞HepG2則無此現象,且僅可在Hep3B中觀察到caspase-3、-7及bcl-2家族蛋白的活化被抑制。因此本篇研究將探討tunicamycin對兩株細胞產生不同抑制作用的機轉。實驗中檢測了許多蛋白的表現量與功能,包括拓樸異構酵素(I, IIα and IIβ)、B型肝炎病毒的相關蛋白、p-glycoprotein及reactive oxygen species (ROS)的釋放程度。結果顯示上述蛋白、酵素或是ROS皆無法解釋tunicamycin主導的抗藥性為何僅出現在Hep3B而非HepG2,且使用p53 siRNA後亦可排除此腫瘤抑制基因參與抗藥性產生的機轉。合併處理tunicamycin與單獨處理camptothecin/etoposide相較時,僅在Hep3B中可觀察到許多細胞週期調控蛋白的表現會受影響。此外,由先給予camptothecin/etoposide而tunicamycin後加的實驗中,顯示當後加的時間點越晚,可觀察到tunicamycin在Hep3B對於camptothecin/etoposide的抗藥性貢獻會消失,此表示細胞週期的調控在此處的必要性。我們亦觀察到了內質網壓力的指標蛋白GRP78之表現量與Hep3B細胞的存活率有良好的相關性。進行GRP78 siRNA實驗後,可觀察到tunicmaycin導致的細胞凋亡現象,顯示了GRP78可促進細胞存活的角色,且同時tunicamycin主導的Hep3B抗藥性會因此消失。因此GRP78在Hep3B的抗藥性中扮演了重要的角色。由上述的實驗數據可知,tunicamycin在Hep3B而非HepG2造成對camptothecin/etoposide產生抗藥性的原因,是由於在Hep3B中tunicamycin的合併使用可經由改變細胞週期的調控,以及增加GRP78的表現來提供對抗藥性的貢獻。 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma is a very common malignancy and is chemoresistant to clinical chemotherapeutic agents. Camptothecin and etoposide are two well-known anticancer drugs, targeting topoisomerase I and II, respectively. Tunicamycin, an N-glycosylation inhibitor, can cause unfolded protein response (UPR) and be widely used as pharmacological inducer of endoplasmic reticulum (ER) stress. Our data demonstrated that the combined co-treatment with tunicamycin could prevent cell apoptosis induced by camptothecin or etoposide in hepatocellular carcinoma Hep3B other than HepG2 cells, and only inhibit the activation of caspase-3、-7 and bcl-2 family protein in Hep3B cell. The following assessments were conducted to characterize the varied responses to tunicamycin inhibition in these two cell lines. Several protein expressions and functions were examined in this study, including topoisomerases (I, IIα and IIβ), HBV-related protein, p-glycoprotein and the levels of reactive oxygen species (ROS).The data demonstrated that none of these proteins, enzymes or free radicals could explain tunicamycin-mediated resistance in Hep3B but not in HepG2 cells. Using siRNA to knockdown p53, the data also excluded the involvement of this tumor suppressor gene. During the co-treatment, the expression of several cell cycle regulator could be changed compare to alone treat TOP posions. Furthermore, in the design of post-treatment of tunicamycin after camptothecin/etoposide addition, the results showed that tunicamycin-reversed effect declined when the duration of post-treatment was increased in Hep3B cells, indicating the necessity of cell cycle regulation for the reduction of camptothecin/etoposide effect. GRP78 expression had a good correlation with survival percentage in Hep3B other than HepG2. By using siRNA approaches, the data demonstrated that the knockdown of GRP78 expression induced a moderate increase of tunicamycin-induced apoptosis, revealing the pro-survival properties of GRP78, and tunicamycin-mediated resistance to camptothecin/etoposide action in Hep3B could be declined, accompanying the change of cell cycle distribution. The data suggested that GRP78 played an important role in the resistant mechanism. Taken together, the data suggest that tunicamycin could cause resistance to TOP poisons through cell cycle regulation, and induce an increase of GRP78 expression contributing to resistance of TOP poisons in Hep3B other than HepG2. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T01:15:34Z (GMT). No. of bitstreams: 1 ntu-96-R94423002-1.pdf: 6504042 bytes, checksum: 39c4bd9372a8a7776a76ecda31f98d0d (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 縮寫表••••••••••••••••••••••••••• Ⅰ
英文摘要•••••••••••••••••••••••••• Ⅲ 中文摘要•••••••••••••••••••••••••• Ⅴ 研究動機••••••••••••••••••••••••••• 1 背景••••••••••••••••••••••••••• 2 實驗材料••••••••••••••••••••••••• 19 實驗方法••••••••••••••••••••••••• 20 1、 細胞培養••••••••••••••••••••• 20 2、 細胞計數••••••••••••••••••••• 20 3、 抑制細胞生長的測定法•••••••••••••••• 21 4、 流式細胞儀•••••••••••••••••••••• 22 (1) 測定細胞凋亡與細胞週期•••••••••••••• 22 (2) Cyclin B1-PI雙染••••••••••••••••• 22 (3) 測定細胞過氧化氫含量••••••••••••••••• 23 (4) 測定p-glycoprotein功能••••••••••••••••• 23 5、 蛋白質萃取與定量••••••••••••••••• 24 6、 西方墨點法•••••••••••••••••••••••••• 24 7、 細胞轉染••••••••••••••••••••••• 27 8、 資料分析•••••••••••••••••••••• 27 實驗結果••••••••••••••••••••••••••• 29 討論••••••••••••••••••••••••••• 39 結論••••••••••••••••••••••••••• 50 圖表••••••••••••••••••••••••••• 51 參考文獻••••••••••••••••••••••••••• 77 | |
dc.language.iso | zh-TW | |
dc.title | 內質網壓力抑制拓樸異構酵素抑制劑引發之細胞凋亡在人類肝癌細胞的機轉探討 | zh_TW |
dc.title | Characterization of ER Stress-Mediated Inhibition of Topoisomerase Inhibitor-Induced Apoptosis in HCC | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃聰龍,楊家榮,孔繁璐,沈麗娟 | |
dc.subject.keyword | 內質網壓力,拓樸異構酵素抑制劑,肝癌, | zh_TW |
dc.subject.keyword | tunicamycin,topoisomerase poison,HCC, | en |
dc.relation.page | 88 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 6.35 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。